Trial Profile
Study of efficacy and safety of regorafenib for the treatment of hepatocellular carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2018
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 16 May 2018 New trial record
- 14 Apr 2018 Results presented at The International Liver Congress 2018